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sample, and tumour stage were reported for each study. Life expectancy was derived from life tables, while QoL was obtained from a study that used the EORTC QOL C-30 instrument.
Sources searched to identify primary studies
PubMed was searched for data on the effectiveness of ACT treatments. Of the 3,994 articles initially identified, 10 studies were finally included.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Ten primary studies were included in the review. Three more studies were used to derive other data.
Methods of combining primary studies
The primary estimates were not combined as the authors selected a range of estimates from among all values available from the literature.
Investigation of differences between primary studies
Results of the review
The FEC regimen improved 5-year survival in early BC by 3 to 7% in comparison with CMF. A 5% improvement was used in the base-case.
The life expectancy for a 50-year-old woman was 28.57 years while that of a 60-year-old woman was 19.45 years.
CMF saved 2.45 life-years per patient treated.
No difference in QoL between CMF and FEC was observed.
Measure of benefits used in the economic analysis
The summary benefit measure used was the number of life-years gained with the new regimen over the standard approach. This was calculated by multiplying the life expectancy of a patient by the improvement in survival with FEC found in the literature. An annual discount rate of 3% was applied.
Direct costs
The cost analysis was conducted from a societal perspective. The direct costs were for drugs, travelling, outpatient clinic and drug administration. The unit costs and the quantities of resources used were not presented separately. The costs came from the University Hospital of North Norway, national price lists, and the Regional Health Authority of Northern Norway. Discounts obtained by regional authorities were also considered (LIS agreement). To reflect actual treatment patterns in Norway, the resource use data were based on the authors' experience at their institution. An annual discount rate of 3% was applied to the costs, which was appropriate as a 20-year timeframe was considered. The price year was 2004.
The authors justified the choice of the comparators, which were appropriate for the study question. The new regimen (FEC) has taken over the role of CMF in most countries. You should decide whether they are valid interventions in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence came from published sources, which were identified through a review of the literature. Details of the conduct and methods of the review were provided, and several characteristics of the primary studies were described. Most of the studies were clinical trials, which should have ensured a high internal validity. However, the primary estimates were not combined and a single point estimate was chosen from among those available in the literature. Other data used to assess the benefits of the two ACT regimens were obtained from published studies. The impact of changing clinical data on the results of the study was only partially investigated using a univariate sensitivity analysis.
Validity of estimate of measure of benefit
The choice of life-years as the summary benefit measure was appropriate since the impact of the interventions on survival is a relevant dimension of health for women with early BC. The effect of the ACT regimens on QoL was not considered since published studies showed that the two treatments were equally effective.
Validity of estimate of costs
The cost analysis was carried out from a societal perspective, which was appropriate as productivity losses associated with early BC might be relevant. The approach used to assess the indirect costs was reported and an alternative method was also used. However, the unit costs and the quantities of resources used were not given for direct costs, which could limit the possibility of replicating the analysis in other settings. Statistical analyses of the costs were not performed, but the impact of different doses and different approaches for the cost calculations was considered. The price year was reported, which will facilitate reflation exercises in other time periods. The impact of changes in the discount rates was also investigated.
